Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater.
Jessica Zhou, Charles C Hsu, Jordan M Winter...
https://pubmed.ncbi.nlm.nih.gov/19541379/Actively Recruiting
Led by Fondazione Poliambulanza Istituto Ospedaliero · Updated on 2023-10-05
400
Participants Needed
1
Research Sites
52 weeks
Total Duration
Ampullary adenocarcinoma AAC is a rare type of gastrointestinal cancer with different survival rates depending on its subtype, especially the aggressive pancreatobiliary PB subtype. This research aims to study tailored adjuvant chemotherapy treatments based on the cancers histopathology to improve survival outcomes. The study is a phase II prospective single-arm multicenter cohort trial enrolling 200 patients with resected AAC, split evenly between intestinal and PBmixed subtypes. Participants with intestinal subtype AAC will receive CAPOX chemotherapy cycles every 3 weeks, while those with PB and mixed subtypes will receive modified FOLFIRINOX chemotherapy every 2 weeks for 8 to 12 cycles. The study compares outcomes with patients not treated according to this regimen from participating centers. Both groups include patients willing and unwilling to receive adjuvant chemotherapy due to logistics or preference. During the study, participants will be monitored for up to 5 years with evaluations including disease-free survival at 3 and 5 years, overall survival, and quality of life questionnaires. Researchers will collect clinical data to assess treatment effects and follow participants after surgery and chemotherapy to evaluate safety and long-term outcomes. The total participation duration varies depending on follow-up and assessment schedules.
CONDITIONS
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.
M
Moh'd Abu Hilal, MD, PhD
B
Bas Uijterwijk
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione Poliambulanza Istituto Ospedaliero
Lead Sponsor
Associazione Italiana per la Ricerca sul Cancro
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 16 to 36 weeks depending on regimen and cycle completion
Participants receive adjuvant chemotherapy with either 8 to 12 cycles of FOLFIRINOX repeated every 2 weeks or 8 cycles of CAPOX repeated every 3 weeks following curative intent surgery.
Visits every 2 or 3 weeks during chemotherapy cycles
Duration - Up to 3 years
Participants are monitored for disease-free survival and overall survival, and complete quality of life questionnaires after chemotherapy treatment ends.
Periodic visits for assessments during follow-up period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Jessica Zhou, Charles C Hsu, Jordan M Winter...
https://pubmed.ncbi.nlm.nih.gov/19541379/Louisa Bolm, Kristina Ohrner, Gennaro Nappo...
https://pubmed.ncbi.nlm.nih.gov/31987649/Bas A Uijterwijk, Daniel H L Lemmers, Dorine S Klei...
https://pubmed.ncbi.nlm.nih.gov/41812337/John P Neoptolemos, Malcolm J Moore, Trevor F Cox...
https://pubmed.ncbi.nlm.nih.gov/22782416/Michael J Overman, Gauri R Varadhachary, Scott Kopetz...
https://pubmed.ncbi.nlm.nih.gov/19164203/Thierry Conroy, Pascal Hammel, Mohamed Hebbar...
https://pubmed.ncbi.nlm.nih.gov/30575490/A L Moekotte, G Malleo, S van Roessel...
https://pubmed.ncbi.nlm.nih.gov/32259295/Fondazione Poliambulanza Istituto Ospedaliero
Lead Sponsor
Associazione Italiana per la Ricerca sul Cancro
Collaborating Sponsor